Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2.
We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies.
Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US.
For more information, please visit https://www.veronapharma.com.
-
Industry
-
Biotechnology Research
-
Company size
-
51-200 employees
-
Headquarters
-
London, UK
-
Type
-
Public Company
-
Founded
-
2005
-
Specialties
-
Novel therapies for chronic respiratory diseases , COPD, CF, and Asthma
